{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:15Z","timestamp":1787020215586,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Science and Technology Agency of Qinghai Province","award":["2022-ZJ-719"],"award-info":[{"award-number":["2022-ZJ-719"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14712-w","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:54:29Z","timestamp":1755503669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Weixing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"2","key":"14712_CR1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197\u2013206.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"14712_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"14712_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.21.01715","volume":"40","author":"DCC Tsui","year":"2022","unstructured":"Tsui DCC, Camidge DR, Rusthoven CG. Managing central nervous system spread of lung cancer: the state of the art. J Clin Oncol. 2022;40(6):642\u201360.","journal-title":"J Clin Oncol"},{"key":"14712_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126832","author":"A Del Conte","year":"2022","unstructured":"Del Conte A, De Carlo E, Bertoli E, Stanzione B, Revelant A, Bertola M, Spina M, Bearz A. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126832.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"14712_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14712_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78\u201384.","journal-title":"Lung Cancer"},{"issue":"8","key":"14712_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41416-022-01929-w","volume":"127","author":"A Rizzo","year":"2022","unstructured":"Rizzo A. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br J Cancer. 2022;127(8):1381\u20132.","journal-title":"Br J Cancer"},{"issue":"10","key":"14712_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/CAD.0000000000001118","volume":"32","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Dall\u2019Olio FG, Altimari A, Giunchi F, Ardizzoni A. Role of PD-L1 assessment in advanced NSCLC: does it still matter? Anticancer Drugs. 2021;32(10):1084\u20135.","journal-title":"Anticancer Drugs"},{"key":"14712_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213689","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16213689.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"14712_CR10","first-page":"624","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, Rizzo A. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624.","journal-title":"Support Care Cancer"},{"issue":"12","key":"14712_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455\u201366.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"14712_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The liver-immunity nexus and cancer immunotherapy. Clin Cancer Res. 2022;28(1):5\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"14712_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/annonc\/mdy041","volume":"29","author":"EE Vokes","year":"2018","unstructured":"Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Ar\u00e9n Frontera O, Gettinger S, Holgado E, Spigel D, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959\u201365.","journal-title":"Ann Oncol"},{"issue":"2","key":"14712_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309\u201323.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"14712_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","volume":"88","author":"KL Wu","year":"2015","unstructured":"Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88(2):187\u201394.","journal-title":"Lung Cancer"},{"issue":"6","key":"14712_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 2019;40(6):511\u201323.","journal-title":"Trends Immunol"},{"key":"14712_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153788","author":"R Ephraim","year":"2022","unstructured":"Ephraim R, Fraser S, Nurgali K, Apostolopoulos V. Checkpoint markers and tumor microenvironment: what do we know? Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153788.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"14712_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(3):387\u201397.","journal-title":"Lancet Oncol"},{"issue":"9","key":"14712_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00262-018-2182-4","volume":"67","author":"C Putzu","year":"2018","unstructured":"Putzu C, Cortinovis DL, Colonese F, Canova S, Carru C, Zinellu A, Paliogiannis P. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab. Cancer Immunol Immunother. 2018;67(9):1349\u201353.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"14712_CR20","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14712_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"4","key":"14712_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr., Novello S, Orlandi F, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 impower132 trial. J Thorac Oncol. 2021;16(4):653\u201364.","journal-title":"J Thorac Oncol"},{"key":"14712_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647.","journal-title":"BMJ"},{"key":"14712_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"issue":"10","key":"14712_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10): e76654.","journal-title":"PLoS ONE"},{"key":"14712_CR26","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim SJ, Lee J, R\u00fccker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41: e2019013.","journal-title":"Epidemiol Health"},{"key":"14712_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12874-016-0184-5","volume":"16","author":"M Law","year":"2016","unstructured":"Law M, Jackson D, Turner R, Rhodes K, Viechtbauer W. Two new methods to fit models for network meta-analysis with random inconsistency effects. BMC Med Res Methodol. 2016;16:87.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"14712_CR28","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"14712_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(5):709\u201317.","journal-title":"JAMA Oncol"},{"issue":"2","key":"14712_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, Wu L, Wang X, Viguro M, Makharadze T, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42(2):198\u2013208.e193.","journal-title":"Cancer Cell"},{"issue":"7","key":"14712_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, D\u00f3mine M, Cheng SY, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881\u201395.","journal-title":"Ann Oncol"},{"issue":"9","key":"14712_CR32","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512\u201322.","journal-title":"J Thorac Oncol"},{"key":"14712_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008189","author":"DP Carbone","year":"2024","unstructured":"Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, et al. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008189.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"14712_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102065","volume":"8","author":"H Borghaei","year":"2023","unstructured":"Borghaei H, O\u2019Byrne KJ, Paz-Ares L, Ciuleanu TE, Yu X, Pluzanski A, Nagrial A, Havel L, Kowalyszyn RD, Valette CA, et al. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO Open. 2023;8(6): 102065.","journal-title":"ESMO Open"},{"issue":"2","key":"14712_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23(2):220\u201333.","journal-title":"Lancet Oncol"},{"issue":"6","key":"14712_CR36","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s43018-023-00578-z","volume":"4","author":"C Zhou","year":"2023","unstructured":"Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, et al. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nat Cancer. 2023;4(6):860\u201371.","journal-title":"Nat Cancer"},{"issue":"1","key":"14712_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","volume":"18","author":"G de Castro Jr.","year":"2023","unstructured":"de Castro G Jr., Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, et al. NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC. J Thorac Oncol. 2023;18(1):106\u201319.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"14712_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289\u2013308.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"14712_CR39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtho.2021.10.023","volume":"17","author":"NB Leighl","year":"2022","unstructured":"Leighl NB, Laurie SA, Goss GD, Hughes BGM, Stockler M, Tsao MS, Hwang DM, Joubert P, Kulkarni S, Blais N, et al. CCTG BR34: a randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. J Thorac Oncol. 2022;17(3):434\u201345.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"14712_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","volume":"41","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41(3):651\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14712_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03484-1","volume":"24","author":"XC Zhang","year":"2024","unstructured":"Zhang XC, Zhou YW, Wei GX, Luo YQ, Qiu M. Locoregional therapies combined with immune checkpoint inhibitors for liver metastases. Cancer Cell Int. 2024;24(1): 302.","journal-title":"Cancer Cell Int"},{"issue":"7528","key":"14712_CR42","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"key":"14712_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007218","author":"JY Deng","year":"2023","unstructured":"Deng JY, Gou Q, Yang L, Chen ZH, Yang MY, Yang XR, Yan HH, Wei XW, Liu JQ, Su J, et al. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007218.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"14712_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4143\/crt.2021.764","volume":"54","author":"Q Yin","year":"2022","unstructured":"Yin Q, Dai L, Sun R, Ke P, Liu L, Jiang B. Clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with liver metastases: a network meta-analysis of nine randomized controlled trials. Cancer Res Treat. 2022;54(3):803\u201316.","journal-title":"Cancer Res Treat"},{"key":"14712_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.978069","volume":"12","author":"H Xia","year":"2022","unstructured":"Xia H, Zhang W, Zhang Y, Shang X, Liu Y, Wang X. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. Front Oncol. 2022;12: 978069.","journal-title":"Front Oncol"},{"key":"14712_CR46","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3389\/fonc.2020.01098","volume":"10","author":"K Yang","year":"2020","unstructured":"Yang K, Li J, Bai C, Sun Z, Zhao L. Efficacy of immune checkpoint inhibitors in non-small-cell lung cancer patients with different metastatic sites: a systematic review and meta-analysis. Front Oncol. 2020;10:1098.","journal-title":"Front Oncol"},{"issue":"1","key":"14712_CR47","doi-asserted-by":"publisher","first-page":"1746113","DOI":"10.1080\/2162402X.2020.1746113","volume":"9","author":"S Li","year":"2020","unstructured":"Li S, Sun S, Xiang H, Yang J, Peng M, Gao Q. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. Oncoimmunology. 2020;9(1):1746113.","journal-title":"Oncoimmunology"},{"issue":"21","key":"14712_CR48","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1158\/1078-0432.CCR-15-1636","volume":"23","author":"S Milette","year":"2017","unstructured":"Milette S, Sicklick JK, Lowy AM, Brodt P. Molecular pathways: targeting the microenvironment of liver metastases. Clin Cancer Res. 2017;23(21):6390\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"14712_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14712_CR50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17(1):54.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14712_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"key":"14712_CR52","doi-asserted-by":"publisher","first-page":"153473542311645","DOI":"10.1177\/15347354231164584","volume":"22","author":"H Xu","year":"2023","unstructured":"Xu H, Ming P, Zhao Z, Zhao N, Zhou D, Tang X, Cao D. Assessing the relationship between liver metastases and the survival of patients with non-small cell lung cancer after immune checkpoint inhibitors treatment: a systematic review and meta-analysis. Integr Cancer Ther. 2023;22:15347354231164584.","journal-title":"Integr Cancer Ther"},{"issue":"8","key":"14712_CR53","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodr\u00edguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"14712_CR54","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodr\u00edguez-Abreu D, Moro-Sibilot D, Thomas CA, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"14712_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jtho.2023.09.1445","volume":"19","author":"M Reck","year":"2024","unstructured":"Reck M, Barlesi F, Yang JC, Westeel V, Felip E, \u00d6zg\u00fcro\u011flu M, Dols MC, Sullivan R, Kowalski DM, Andric Z, et al. Avelumab versus platinum-based doublet chemotherapy as first-line treatment for patients with high-expression programmed death-ligand 1-positive metastatic NSCLC: primary analysis from the phase 3 JAVELIN lung 100 trial. J Thorac Oncol. 2024;19(2):297\u2013313.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"14712_CR56","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","volume":"28","author":"S Peters","year":"2022","unstructured":"Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022;28(9):1831\u20139.","journal-title":"Nat Med"},{"key":"14712_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174333","author":"M Xie","year":"2022","unstructured":"Xie M, Li N, Xu X, Xu Y, Li H, Zhu L, Sheng J, Zhou Z, Fan Y. The efficacy of PD-1\/PD-L1 inhibitors in patients with liver metastasis of non-small cell lung cancer: a real-world study. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14174333.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"14712_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02636-x","volume":"18","author":"XL Wei","year":"2020","unstructured":"Wei XL, Luo X, Sheng H, Wang Y, Chen DL, Li JN, Wang FH, Xu RH. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. J Transl Med. 2020;18(1): 475.","journal-title":"J Transl Med"},{"issue":"5","key":"14712_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417\u201324.","journal-title":"Cancer Immunol Res"},{"key":"14712_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362: k3529.","journal-title":"BMJ"},{"key":"14712_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021;11: 562315.","journal-title":"Front Oncol"},{"issue":"3","key":"14712_CR62","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375\u201384.","journal-title":"JAMA Oncol"},{"issue":"1","key":"14712_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14712-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14712-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14712-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:38:06Z","timestamp":1757432286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14712-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14712"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14712-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1332"}}